Vascular effects of nonsteroidal antiinflammatory drugs

Soubrier, Martin; Rosenbaum, David P.; Tatar, Zuzana; Lahaye, Clément; Dubost, Jean‐Jacques; Mathieu, Sylvain

doi:10.1016/j.jbspin.2012.12.002

Cited by 26 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…29–31, 36, 37, 52–59 In fact, a correlation exists between elevated inflammatory responses and disease progression, 31, 57, 60, 61 and immunosupression can delay or even arrest the progression of CVD. 62–67 Second , following an acute injury, the BM cells with angiogenic and reparative properties such as endothelial progenitor cells (EPCs) 17, 68–73 are immediately recruited to the site of injury, aiding in repair of the tissue damage. 74–78 Unfortunately, some patients with advancing CVD and other related diseases have significantly decreased pools of EPCs, 79, 80 and this decreased vascular potential further exacerbates the dysfunctional vasculature already seen in CVD.…”

Section: Role Of Bone Marrow In Cardiovascular Health and Diseasementioning

confidence: 99%

Functional Neural–Bone Marrow Pathways

et al. 2014

View full text Add to dashboard Cite

Section: Role Of Bone Marrow In Cardiovascular Health and Diseasementioning

confidence: 99%

Functional Neural–Bone Marrow Pathways

et al. 2014

View full text Add to dashboard Cite

“…Cardiovascular disease (CVD) is the leading cause of death in patients with ankylosing spondylitis (AS) (1). The increased prevalence of cardiovascular (CV) morbidity and mortality in patients with AS has been attributed to AS-specific CV manifestations, traditional CVD risk factors, systemic inflammation, and nonsteroidal anti-inflammatory drug (NSAID) use (2,3).…”

Section: Introductionmentioning

confidence: 99%

Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis

et al. 2019

View full text Add to dashboard Cite

Objective: The aim of the present study was to compare patients with ankylosing spondylitis (AS) with healthy controls with respect to subclinical atherosclerotic cardiovascular disease (CVD). Methods: A total of 44 patients with AS with no history of CVD, diabetes mellitus, hypertension, chronic kidney disease, and lipid-lowering drug use were compared with 40 age-and sex-matched healthy controls with respect to carotid intima-media thickness (CIMT) and pulse wave velocity (PWV), which are surrogate markers of subclinical atherosclerosis. Correlation analysis was also performed to examine the association between surrogate markers and disease activity with inflammation [Ankylosing spondylitis disease activity score with C-reactive protein (ASDAS-CRP)]. Results: In addition to age and sex, both groups were comparable with respect to cigarette smoking, body mass index, and high-density lipoprotein cholesterol (p=0.425, p=0.325, and p=0.103, respectively). The level of total cholesterol was significantly lower in patients with AS (p=0.002). Nonsteroidal anti-inflammatory drug and tumor necrosis factor alpha inhibitor use ratios in patients with AS were 79.5% and 65.9%, respectively. There was no significant difference between both groups regarding PWV and CIMT (p=0.788 and p=0.253, respectively). In patients with AS, there was a significant correlation between ASDAS-CRP and CIMT (r=0.315, p=0.038), but the correlation between ASDAS-CRP and PWV was not significant (r=−0.183, p=0.234). Conclusion:The results of the present study could not provide sufficient evidence whether disease activity with inflammation caused subclinical atherosclerotic CVD in patients with AS without overt CVD. The increased atherosclerotic CVD risk is most probably multifactorial in patients with AS, but the extent of the contribution of disease activity with inflammation to increased atherosclerosis is controversial. (Anatol J Cardiol 2019; 22: 185-91) ABSTRACT Hatipsoylu et al.

show abstract

“…Although glucocorticoids have proven efficacy on clinical symptoms and structural damage, their side effects (hypertension, insulin resistance, weight gain, osteoporosis, fractures, infections, gastric ulcer, adrenal suppression) restrict their longterm use. Other treatments also have highly unfavorable safety profiles in the elderly: drug interactions, renal failure, cardiovascular events and gastrointestinal bleeding for NSAIDs; dependence, respiratory depression and confusion for narcotics [10]. The last ten years have seen profound changes in therapeutic management.…”

Section: The Era Of Tight Control?mentioning

confidence: 99%